Ownership history in Caligan Partners LP Β· 5 quarters on record
This page tracks every 13F SEC filing in which Caligan Partners LP reported a position in ABIVAX SA (ABVX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Caligan Partners LP outperformed the S&P 500 by +1059.1% annually on this ABVX position. Timing score: 50% (2/4 decisions correct). Average cost basis: $7.07. Maximum drawdown during holding period: β14.6%.
π₯ Exceptional β beat the S&P 500 by 1059.1% per year on this position.
4 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
2 of 4 add/trim decisions correct
Best entry: $6.25 (2025 Q1) Β· Worst: $7.65 (2025 Q2)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
3 adds Β· 1 trim. Bought during 1 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Caligan Partners LP has been actively increasing its ABVX allocation β a bullish signal from insiders.
Currently 16.12% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.